+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

China Molecular Diagnostics Market, Volume, by Application [Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), Infectious Disease Testing (Virology, HPV), and Genetic Disease Testing (Blood Screening, HLA)]

  • ID: 5181453
  • Report
  • October 2020
  • Region: China
  • 100 Pages
  • Renub Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

Molecular diagnostics plays an important role in the identification of diseases and has gained more public & healthcare specialist attention than ever before. The molecular diagnostics is a technique used for the molecular biological detection of any change in the structure or expression of a patient's genetic material. According to the publisher, China Molecular Diagnostics Market is expected to be US$ 6.3 Billion by 2026.

In recent years, Molecular diagnostics has changed the face of clinical laboratories by offering easy to use automated molecular systems that provide rapid results with less hands-on time. However, huddles for China diagnostic companies are Lack of Government Support, Public Awareness for Molecular Diagnostics test.

COVID-19 effect on Molecular Diagnostics Industry

Besides, COVID-19 has worked as a catalyst for molecular diagnostics industry in China. In order to spread the disease government of China is doing massive number of COVID-19 tests. The types of tests which are done to identify the coronavirus disease are RT-PCR, and rapid anti-body tests also known as serological tests. RT-PCR is considered the ‘gold standard’ frontline test. In this test testing is done by taking a nasal/throat swab from a patient. This test involves extracting ribonucleic acid or RNA, which is the genetic material of the virus. This is a fairly expensive test it requires RNA extracting machines, a laboratory and trained technicians. On the other hand rapid anti-body tests are portable, administered on-site, provide quick answers and are inexpensive too.

China molecular diagnostics market is segmented into three main categories: Oncology Test, Infectious Disease Test, and Genetic Disease Test. Further, the Oncology Test has been segmented into three types: Prostate Cancer, Colorectal Cancer and Breast Cancer. Infectious Disease Test has been further categorized into two main types, which are virology and HPV. Genetic Test has been categorized into HLA and Blood Screening. A blood screening test is a dominating segment in the China molecular genetic testing market. According to this analysis, nearly 441 million molecular diagnostic tests will be performed in China by the end of 2026 of which Virology accounts for one of the most performed test segments.

DICON Clinical Laboratories, Zhejiang Di’an Diagnostics Technology Co., Ltd, Kindstar Global, BGI-Shenzhen, A, Guangzhou Kingmed Diagnostics Center Co. Ltd and OriGene Technologies holds the majority of the market share in China. However, restriction on export is expected to have minimal impact on the manufacturers as the demand is very high in China which is creating a robust revenue pool for manufacturers dealing in the molecular diagnostics sector.

This report titled “China Molecular Diagnostics Market, Volume, by Application [Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), Infectious Disease Testing (Virology, HPV), and Genetic Disease Testing (Blood Screening, HLA)]” provides a complete analysis of China Molecular Diagnostics Market.

By Application

The report studies the market and volume of the following segments in Molecular Diagnostics: Infectious Disease Testing (Virology, HPV), Oncology Testing (Breast Cancer, Colorectal Cancer, Prostate Cancer), and Genetic Disease Testing (Blood Screening, HLA).

Segment Covered in this report are as follows:

Oncology Testing Market and Volume

  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer

Infectious Disease Testing Market and Volume

  • Virology
  • HPV

Genetic Testing Market and Volume

  • Blood Screening
  • HLA

Profiles of Private Clinical Labs and Diagnostic Services Companies in China

  • Zhejiang Di’an Diagnostics Technology Co., Ltd
  • ADICON Clinical Laboratories
  • Guangzhou Kingmed Diagnostics Center Co. Ltd.
  • Kindstar Global (Privately held)
  • BGI-Shenzhen (Privately held)
  • OriGene Technologies (Privately held)
Note: Product cover images may vary from those shown
2 of 4
1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Driver
4.2 Challenges

5. China Molecular Diagnostic Market & Test Volume
5.1 China Molecular Diagnostic Market
5.2 China Molecular Diagnostic Test Volume

6. Market Share - China Molecular Diagnostic Share Analysis
6.1 Segments
6.2 Disease
6.3 Oncology Test
6.4 Genetic Test
6.5 Infectious Disease Test

7. Volume Share - China Molecular Diagnostics
7.1 Segments
7.2 Disease
7.3 Oncology Test
7.4 Infectious Disease Test
7.5 Genetic Test

8. Disease - China Molecular Diagnostic Test Volume
8.1 Oncology Test Volume
8.1.1 Breast Cancer Test Volume
8.1.2 Colorectal Cancer Test Volume
8.1.3 Prostate Cancer Test Volume
8.2 Infectious Disease Test Volume
8.2.1 Virology Test Volume
8.2.2 HPV Test Volume
8.3 Genetic Test Volume
8.3.1 Blood Screening Test Volume
8.3.2 HLA Test Volume

9. Disease - China Molecular Diagnostic Market
9.1 Oncology Testing Market
9.1.1 Breast Cancer Testing Market
9.1.2 Colorectal Cancer Testing Market
9.1.3 Prostate Cancer Testing Market
9.2 Infectious Disease Testing Market
9.2.1 Virology Testing Market
9.2.2 HPV Testing Market
9.3 Genetic Testing Market
9.3.1 Blood Screening Market
9.3.2 HLA Testing Market

10. China Healthcare Insurance Schemes
10.1 China Healthcare Insurance Schemes
10.1.1 New Rural Cooperative Medical Scheme (NRCMS)
10.1.2 Urban Employed Basic Medical Insurance (UEBMI)
10.1.3 Urban Resident Basic Medical Insurance (URBMI)
10.1.4 Private Health Insurance

11. Profiles of Private Clinical Labs and Diagnostic Services Companies
11.1 Zhejiang Di’an Diagnostics Technology Co., Ltd.
11.1.1 Company Overview
11.1.2 Products and Services Offered by Di’an
11.2 ADICON Clinical Laboratories (Privately held)
11.2.1 Company Overview
11.2.2 Products and Services Offered by ADICON
11.3 Guangzhou Kingmed Diagnostics Center Co. Ltd.
11.3.1 Company Overview
11.3.2 Products and Services Offered by Kingmed
11.4 Kindstar Global (Privately held)
11.4.1 Company Overview
11.4.2 Products and Services Offered by Kindstar
11.5 BGI-Shenzhen
11.5.1 Company Overview
11.5.2 BGI’s Innovative Approach
11.6 OriGene Technologies
11.6.1 Company Overview
11.6.2 Products and Services Offered by OriGene

List of Figures:
Figure 3-1: China - Healthcare Spending (Billion US$), 2011 & 2020
Figure 4-1: China - Molecular Diagnostic Market (Million US$), 2015 - 2019
Figure 4-2: China - Forecast for Molecular Diagnostic Market (Million US$), 2020 - 2026
Figure 4-3: China - Molecular Diagnostic Test Volume (Million), 2015 - 2019
Figure 4-4: China - Forecast for Molecular Diagnostic Test Volume (Million), 2020 - 2026
Figure 5-1: China - Molecular Diagnostic Market Share (Percent), 2015 - 2019
Figure 5-2: China - Forecast for Molecular Diagnostic Market Share (Percent), 2020 - 2026
Figure 5-3: China - Molecular Oncology Test Market Share (Percent), 2015 - 2019
Figure 5-4: China - Forecast for Molecular Oncology Test Market Share (Percent), 2020 - 2026
Figure 6-1: China - Molecular Diagnostic Test Volume Share (Percent), 2015 - 2019
Figure 6-2: China - Forecast for Molecular Diagnostic Test Volume Share (Percent), 2020- 2026
Figure 6-3: China - Molecular Oncology Test Volume Share (Percent), 2015 - 2019
Figure 6-4: China - Forecast for Molecular Oncology Test Volume Share (Percent), 2020 - 2026
Figure 7-1: Rural China - Cancer Screening Sites by Cancer Type (Number), 2013
Figure 7-2: China - Oncology Test Volume (Million), 2015 - 2019
Figure 7-3: China - Forecast for Oncology Test Volume (Million), 2020 - 2026
Figure 7-4: China - Breast Cancer Molecular Test Volume (Million), 2015 - 2019
Figure 7-5: China - Forecast for Breast Cancer Molecular Test Volume (Million), 2020 - 2026
Figure 7-6: China - Colorectal Cancer Test Volume (Million), 2015 - 2019
Figure 7-7: China - Forecast for Colorectal Cancer Test Volume (Million), 2020 - 2026
Figure 7-8: China - Prostate Cancer Test Volume (Million), 2015 - 2019
Figure 7-9: China - Forecast for Prostate Cancer Test Volume (Million), 2020 - 2026
Figure 7-10: China - Infectious Disease Test Volume (Million), 2015 - 2019
Figure 7-11: China - Forecast for Infectious Disease Test Volume (Million), 2020 - 2026
Figure 7-12: China - Virology Test Volume (Million), 2015 - 2019
Figure 7-13: China - Forecast for Virology Test Volume (Million), 2020 - 2026
Figure 7-14: China - HPV Test Volume (Thousand), 2015 - 2019
Figure 7-15: China - Forecast for HPV Test Volume (Thousand), 2020 - 2026
Figure 7-16: China - Genetic Test Volume (Million), 2015 - 2019
Figure 7-17: China - Forecast for Genetic Test Volume (Million), 2020 - 2026
Figure 7-18: China - Blood Screening Test Volume (Million), 2015 - 2019
Figure 7-19: China - Forecast for Blood Screening Test Volume (Million), 2020 - 2026
Figure 7-20: China - HLA Test Volume (Thousand), 2015 - 2019
Figure 7-21: China - Forecast for HLA Test Volume (Thousand), 2020 - 2026
Figure 8-1: China - Oncology Testing Market (Million US$), 2015 - 2019
Figure 8-2: China - Forecast for Oncology Testing Market (Million US$), 2020 - 2026
Figure 8-3: China - Breast Cancer Testing Market (Million US$), 2015 - 2019
Figure 8-4: China - Forecast for Breast Cancer Testing Market (Million US$), 2020 - 2026
Figure 8-5: China - Colorectal Cancer Testing Market (Million US$), 2015 - 2019
Figure 8-6: China - Forecast for Colorectal Cancer Testing Market (Million US$), 2020 - 2026
Figure 8-7: China - Prostate Cancer Testing Market (Million US$), 2015 - 2019
Figure 8-8: China - Forecast for Prostate Cancer Testing Market (Million US$), 2020 - 2026
Figure 8-9: China - Infectious Disease Testing Market (Million US$), 2015 - 2019
Figure 8-10: China - Forecast for Infectious Disease Testing Market (Million US$), 2020 - 2026
Figure 8-11: China - Virology Testing Market (Million US$), 2015 - 2019
Figure 8-12: China - Forecast for Virology Testing Market (Million US$), 2020 - 2026
Figure 8-13: China - HPV Testing Market (Million US$), 2015 - 2019
Figure 8-14: China - Forecast for HPV Testing Market (Million US$), 2020 - 2026
Figure 8-15: China - Genetic Testing Market (Million US$), 2015 - 2019
Figure 8-16: China - Forecast for Genetic Testing Market (Million US$), 2020- 2026
Figure 8-17: China - Blood Screening Market (Million US$), 2015 - 2019
Figure 8-18: China - Forecast for Blood Screening Market (Million US$), 2020 - 2026
Figure 8-19: China - HLA Testing Market (Million US$), 2015 - 2019
Figure 8-20: China - Forecast for HLA Testing Market (Million US$), 2020 - 2026
Figure 10-10-1: Kindstar - Collaboration with Hospitals in China (Number), 2006 - 2012

List of Tables:
Table 3-1: China - Major Diagnostic Reagent R&D and Manufacturing Companies in Infectious Diseases, 2010
Table 3-2: Number of hospital beds for every 1,000 people
Table 5-1: China - Molecular Diagnostic Application Market Share (Percent), 2015 - 2019
Table 5-2: China - Forecast for Molecular Diagnostic Application Market Share (Percent), 2020 - 2026
Table 5-3: China - Molecular Genetic Test Market Share (Percent), 2015 - 2019
Table 5-4: China - Forecast for Molecular Genetic Test Market Share (Percent), 2020 - 2026
Table 5-5: China - Molecular Infectious Disease Test Market Share (Percent), 2015 - 2019
Table 5-6: China - Forecast for Molecular Infectious Disease Test Market Share (Percent), 2020 - 2026
Table 6-1: China - Molecular Diagnostic Test Volume Application Share (Percent), 2015 - 2019
Table 6-2: China - Forecast for Molecular Diagnostic Test Volume Application Share (Percent), 2020 - 2026
Table 6-3: China - Molecular Infectious Disease Test Volume Share (Percent), 2015 - 2019
Table 6-4: China - Forecast for Molecular Infectious Disease Test Volume Share (Percent), 2020 - 2026
Table 6-5: China - Molecular Genetic Test Volume Share (Percent), 2015 - 2019
Table 6-6: China - Forecast for Molecular Genetic Test Volume Share (Percent), 2020 - 2026
Note: Product cover images may vary from those shown
3 of 4
  • Zhejiang Di’an Diagnostics Technology Co., Ltd
  • ADICON Clinical Laboratories
  • Guangzhou Kingmed Diagnostics Center Co. Ltd.
  • Kindstar Global (Privately held)
  • BGI-Shenzhen (Privately held)
  • OriGene Technologies (Privately held)
Note: Product cover images may vary from those shown
4 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll